Home > Products > Biosurgery > SURGICEL SNoW™ Absorbable Hemostat

SURGICEL SNoW™ Absorbable Hemostat

SURGICEL SNoW™ Hemostat helps you focus on the procedure, not the bleed. With enhanced speed, handling and performance, one layer of SURGICEL SNoW™ Hemostat is more effective than four layers of SURGICEL® Original Absorbable Hemostat.

Proven bactericidal advantage

SURGICEL® Family of Absorbable Hemostats is bactericidal in vitro against a wide range of gram positive & gram negative organisms250

The SURGICEL® Family of Absorbable Hemostats is the first and only absorbable hemostat proven bactericidal against a broad range of gram-positive and gram-negative organisms including various antibiotic resistant bacteria (MRSA, VRE, PRSP and MRSE).250‡

Request free SURGICEL SNoW™ Hemostat samples  
Proven bactericidal advantage

Faster time to hemostasisβ

Expedite hemostasis with Oxidized Regenerated Cellulose (ORC)

With Oxidized Regenerated Cellulose (ORC) technology, SURGICEL SNoW™ Hemostat expedites hemostasis by serving as a scaffold for platelet adhesion and aggregation that leads to quick clot formation.249 SURGICEL SNoW™ Hemostat provides superior hemostasis compared to SURGICEL® Original Absorbable Hemostat in 43% of the time with reproducible performance among specialties and procedures.

Watch the comparison video   video_library
Faster time to hemostasis

Superior conformability and handlingβ

Non-woven structure increases surface contact to bleeding site252,β

With enhanced conformability and superior handling vs. SURGICEL® Original Absorbable Hemostat,252 SURGICEL SNoW™ Hemostat is easy to deploy and manipulate in laparoscopic surgery.252 Its non-woven structure increases surface contact to bleeding site.252,β

Superior conformability and handling

Increased cost savingsβ

SURGICEL SNoW™ Hemostat & SURGICEL FIBRILLAR™ Hemostat vs SURGICEL Original Hemostat

Offering enhancements vs. SURGICEL Original in hemostatic performance, conformability, and tissue adherence at the bleeding site, resulting in lower product utilization and better patient outcomes. These included 25% less product usage, lowered transfusion cost by 38%-52%, hospital length of stay reduced up to 15% equating to $500-$2,000 in savings, and shortened stay in ICU by up to 20% equating to $200-$2,200 in savings.

View the increased cost saving JME reprint  
Increased cost savings


1 in X 2 in 2081 63713-0020-81 10
2 in X 4 in 2082 63713-0020-82 10
4 in X 4 in 2083 63713-0020-83 10

Site References

  • β Compared to SURGICEL® Original Absorbable Hemostat
  • † Data mined from Premier Hospital Chargemaster Database. Sample size of 170,000 discharges. Independent Retrospective Study: Trinity Partners HE&OR Analysis, 2013, data on file.
  • ‡ Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), penicillin-resistant Streptococcus pneumoniae (PRSP), methicillin-resistant Staphylococcus epidermidis (MRSE).
Thanks for submitting the question. Thanks for submitting the question. Thanks for submitting the question. Thanks for submitting the question. on dev
Share with Friends

Interested in sharing this item?

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Enter the characters shown in the image.
Device Code Translator
Device code translator results

Back to Search